The newest deal has Idenix pairing its IDX719 with two of Johnson & Johnson's hepatitis-C drugs, simeprevir and TMC647055. The drugs are in three different classes, so they should complement each other to help kill the virus.
Idenix will be in charge of running the clinical development program for the potential combo therapy, which will start with a drug-drug interaction study to confirm the drugs are compatible. If all goes well, by the end of the first quarter, Idenix hopes to start a phase 2 trial testing a combination of IDX719 and simeprevir plus a generic called ribavarin. Later, the companies plan to add TMC647055 to the mix with and without the use of ribavarin.
Idenix is up big on the news, which is reasonable; IDX719 isn't all that useful without a partner. And having Johnson & Johnson as a partner could make it easier to partner up IDX184 if it can ever get the drug off the FDA clinical hold it was put on last year.
But being late to the combination party, Idenix has to worry that it might get left out in the cold. Johnson & Johnson is in the driver's seat here since all of these are non-exclusive deals. The health-care giant could seek to be part of multiple cocktails, or it could just throw its entire weight behind the best one.
Investors should be careful not to read too much into this deal. Having a partner doesn't mean that elusive buyout deal is any closer to happening.
Fool contributor Brian Orelli, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.